Kinnate Biopharma Inc. (KNTE) Financials

KNTE Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 190.7 million 18.3 million
2023-06-30 216.1 million 18.5 million
2023-03-31 243.9 million 21.1 million
2022-12-31 278.8 million 20.4 million

KNTE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -25.5 million 5.3 million
2023-06-30 -29.4 million 5.4 million
2023-03-31 -27.7 million 5.4 million
2022-12-31 -23.8 million 4.9 million

KNTE Net Income

No data available :(

KNTE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 167.6 million - 3.4 million
2023-06-30 184.7 million - 3.7 million
2023-03-31 201.0 million - 3.9 million
2022-12-31 201.5 million - 4.2 million

KNTE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 47.1 million
2023-06-30 46.7 million
2023-03-31 45.4 million
2022-12-31 44.1 million

KNTE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 24.5 million 6.6 million -
2023-06-30 9000 26.3 million 7.8 million -
2023-03-31 9000 26.6 million 8.1 million -
2022-12-31 90000 25.2 million 7.5 million -

KNTE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 197000
2023-06-30 - 201000
2023-03-31 - 203000
2022-12-31 - 190000

KNTE

Price: $2.65

52 week price:
1.04
7.19

Earnings Per Share: -2.78 USD

P/E Ratio: -0.84

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 55200

Market Capitalization: 125.0 million

Links: